Medicus Pharma Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
46.7%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
-$0.54next fiscal year
Monitoring Framework
Key Performance Indicators
SkinJect (D-MNA) Phase 2 Clinical Clearance Rate Quarterly73.0%Target: Significant separation from placebo to support registrational trial design
SkinJect (D-MNA) Phase 2 Histological Clearance Rate Quarterly40.0%Target: Histological clearance of nodular basal cell carcinoma
Cash and Cash Equivalents Quarterly6.4MTarget: Maintain sufficient capital to fund ongoing clinical trials
Watch Items
- End-of-Phase 2 (EOP2) FDA Meeting for SkinJectTrigger: FDA feedback on Phase 3 registrational trial design and 505(b)(2) pathway eligibilityAction: Finalize pivotal trial protocol and prepare for Phase 3 initiation or strategic licensing discussions
- Nasdaq Minimum Bid Price ComplianceTrigger: Closing bid price below $1.00 for 30 consecutive business days (Notice received April 2026)Action: Regain compliance by October 19, 2026, potentially utilizing the approved reverse share split of up to 50-for-1
- Teverelix Phase 2b Dose-Optimization Study InitiationTrigger: First patient randomized in the Phase 2b study for advanced prostate cancerAction: Monitor clinical site activation and patient enrollment velocity
Research as of 19 Jun 2026